Revolution Medicines Inc. (RVMD)
The price, the headline numbers and the latest news, in one place.
Revolution Medicines Inc. (RVMD) Stock Price, Analysis & Data
| Bid | 207.94 |
| Market Cap | 44.56B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -1.77B |
| 1.40 | |
| -8.87 | |
| n/a | |
| -34.24 | |
| P/B (ttm) | 27.74 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 4, 2026 |
| Ask | 207.63 |
| Volume | 2,004,020 |
| Avg. Volume (20D) | 2,472,180 |
| Open | 220.72 |
| Previous Close | 221.15 |
| Day's Range | 205.82 - 220.81 |
| 52-Week Range | 37.88 - 224.31 |
| Analyst | Strong Buy |
| Price Target | 239 (14.97%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About RVMD
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets an...
Financial Performance
In 2025, Revolution Medicines's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -1.13B, an increase of 88.52%.
Financial StatementsAnalyst Forecast
According to 21 analyst ratings, the average rating for RVMD stock is "Strong Buy". The 12-month stock price forecast is 239, which is upside of 14.97% from the latest price.
Stock ForecastsEarnings Surprise
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -3.06 misses estimates by -1.00, with -133.59% YoY decline.
Analysts project revenue of ... Upgrade
